LB Pharmaceuticals Inc (LBRX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
LB Pharmaceuticals Inc (LBRX) advanced +0.80% to $40.15, trading at 72% of its 52-week range ($14.32 – $50.16). Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.
Guggenheim Securities reiterated its buy rating on LB Pharmaceuticals and named the biotechnology company a top investment idea, citing promising clinical data for its experimental schizophrenia drug LB-102 and potential
LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The com
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LBRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LBRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, LB Pharmaceuticals Inc (LBRX) ranks #543 by composite RQD confidence (43/100, grade D-) and #327 by equity capitalization ($1.30B). Within this direct 5-issuer industry benchmark cohort, LBRX leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with LBRX at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LBRX
ACTIVE
LB Pharmaceuticals Inc | D- | 43/100 | — | — | -8.4% | +0.80% | $1.30B | Benchmark Subject |
| SNDX Syndax Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -1.19% | $1.26B | /sndx-vs-lbrx → |
| NKTR Nektar Therapeutics | E | 33/100 | — | 96.0% | -35.0% | +1.63% | $1.34B | /nktr-vs-lbrx → |
| KARD Kardigan Inc. | C- | 61/100 | — | — | — | +4.22% | $1.34B | /kard-vs-lbrx → |
| OPK OPKO Health Inc. | D- | 39/100 | — | 33.9% | -10.2% | +2.47% | $1.24B | /opk-vs-lbrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), LB Pharmaceuticals Inc (LBRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$25.2M, operating cash flow of -$35.2M, and free cash flow of -$35.3M (+34.5% YoY). On the balance sheet, LBRX closed FY2025 with $312.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$25.2M | -$35.2M | -$35.3M | $312.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$63.1M | -$53.1M | -$53.8M | $33.5M | — |
As of 2026-11-01, LB Pharmaceuticals Inc (NASDAQ: LBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $40.15 (+0.80% 1D, market cap $1.30B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LBRX ranks #543 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LBRX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -8.4%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.26B) and NKTR (Nektar Therapeutics) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.34B). Among the 5-stock peer group, LBRX leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).
Per LBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001691082), LB Pharmaceuticals Inc generated $0 in revenue, -$25.2M in net income, and -$35.3M in free cash flow against $312.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LBRX last traded at $40.15 (+0.80% on volume of 400,682 shares), positioning the stock -2.97% below its 50-day simple moving average ($41.38) and +23.27% above its 200-day simple moving average ($32.57). Across its 52-week range of $14.32 to $50.16, LBRX sits at the 72.1% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($35.13 to $45.17).
Why LBRX Stock advanced +0.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.